In 2017, the World Health Organization re‒classified pituitary adenomas based on hormone‒producing ability and pituitary adenohypophyseal cell lineage. Non‒functioning pituitary adenomas account for approximately half of all said tumors, often presenting as visual acuity and visual field disturbances. Currently, no effective pharmacologic therapy has been established for non‒functioning pituitary adenomas. Therefore, surgical treatment is the first line of treatment, with endoscopic surgery becoming the mainstream choice. The simultaneous combined supra‒ and infrasellar approach is effective in treating giant pituitary adenomas, while stereotactic radiotherapy is effective in residual and recurrent tumors. Non‒ functioning pituitary adenomas are benign tumors with a promising long‒term prognosis, and appropriate hormone replacement is required to maintain the patient’s quality of life.
All Science Journal Classification (ASJC) codes
- Clinical Neurology